Antidepressant Medication or Short-Term Psychodynamic Psychotherapy for Depression? A Systematic Review and Meta-Analysis of Individual Participant Data.

by Frederik J. Wienicke, Jack J. M. Dekker, Jaap Peen, Henricus L. Van, Jacques P. Barber, Kevin S. McCarthy, Nili Solomonov, Hasse Karlsson, Jarmo Hietala, Jaime López-Rodríguez, Valerio Villamil-Salcedo, Jos W. R. Twisk, Zachary D. Cohen, Pim Cuijpers, and Ellen Driessen

BACKGROUND: Antidepressant medication (ADM) and short-term psychodynamic psychotherapy (STPP) are commonly utilized treatments for depression, but it is unclear which works best for whom. Individual participant data (IPD) meta-analyses can provide more precise effect estimates than conventional meta-analyses and identify patient-level moderators. This IPD meta-analysis examined the efficacy and moderators of ADM versus STPP for depression.

# **METHODS:**

# **Search Strategy**

- Systematic literature search
- Extensive search string (synonyms: *Psychodynamic Psychotherapy*, *Depression*)

# **Study Selection**

- RCT ADM vs STPP on depressed adults
- *N* ≥ 10, ≥ 18 y/o, unipolar mood disorder of elevated depressive symptoms

### Measures

- Outcome:
- 1st: Depression at post-treatment
- $2^{\text{nd:}}$  Any outcome assessed in  $k \ge 2$
- Moderators:
- Sociodemographic, clinical, or psychological characteristic assessed in  $k \ge 2$ , before treatment

### **Data Analysis**

- One stage IPD meta-analysis
- Mixed effects models (3-Level: study, participant, time point)
- Treatment outcome models:
- $y = \beta_0 + \beta_1 time + \beta_2 time x treatment$
- Moderator models:
- $y = \beta_0 + \beta_1 time +$   $+\beta_2 time * treatment + \beta_3 time * moderator$  $+\beta_3 moderator + \beta_4 time * moderator * treatment$
- Random intercept (study & participant)
- Fixed slopes



Antidepressants seem to have a small superiority over short-term psychodynamic psychotherapy in treating adult depression at the end of treatment.

More severely depressed patients
benefit more from antidepressants
than STPP in the short term.



### **RESULTS:**

### **Included Studies**


- Obtained IPD k = 4/5 (N = 310/394)
- STPP: Luborsky, de Jonghe, Bellak, Malan
- Antidepressants: SSRIs and SNRIs
- 8 to 20 sessions of STPP
- Follow-up assessments 6 to 28 months
- Age M = 37.6 (SD = 10.6), 65.5% female

#### **Treatment Outcomes**

- ADM superior over STPP:
- Clinician-rated depressive symptoms (post-tx)
   d = 0.28, 95% CI [0.03, 0.53], p = .031
- No significant differences:
- Self-reported depression, anxiety, general psychopathology, physical health (post-tx)
- Clinician-rated depressive symptoms (FU)

#### **Moderators**

• **ADM more efficacious** than STPP at post-treatment for participants with **more severe baseline depression** d = 0.24, 95% CI [0.08, 0.40], p = .004



## **DISCUSSION:**

- Treatment outcomes are similar IPD-MA: ADM vs CBT
- Differences between clinician-rated vs self-reported depressive symptoms might be influenced by assessment biases
- Moderator finding in line with current practices and guidelines

### Strengths

- IPD allowed for ITT analyses, standardizing analysis, adjusting for baseline differences
- Examining moderators at participant-level

### Limitations

- Midsized sample
- IPD not obtained from one studies
- Observational nature of moderator findings

# **Clinical & Research Implications**

- Similar improvements can be expected for most outcomes with ADM & STPP
- Depression severity should be considered when choosing between ADM & STPP
- Further research large-scale RCTs needed including a range of outcome measures and potential moderators

